Belatacept is the first costimulatory blockade agent approved for maintenance immunosuppression in kidney transplant recipients. Clinical results have indicated that belatacept is associated with superior renal function and improved metabolic profile; however, higher incidence of acute rejection and posttransplant lymphoproliferative disorder are the shortcomings of this agent. In this study, ASP2409, a new cytotoxic T-lymphocyte associated protein 4-immunoglobulin possessing 14-fold higher in vitro CD86 binding affinity than belatacept, was tested for renal allograft survival in cynomolgus monkeys. ASP2409 monotherapy dose-dependently prolonged renal allograft survival. Low-dose ASP2409 in combination with a subtherapeutic dose of tacrolimus showed much longer median survival time than monotherapy. Similar allograft survival results were observed in regimens based on high-dose ASP2409, belatacept, and therapeutic-dose tacrolimus. The results of renal allograft histopathology with highdose ASP2409-based regimens were not inferior to the belatacept-based regimen. Moreover, higher frequencies of FoxP3-positive regulatory T cells in renal allografts were observed in ASP2409-and belatacept-based regimens compared with tacrolimusbased regimens. No serious side effects related to ASP2409 administration were found during the study. These data suggest that ASP2409 is a promising candidate for calcineurin inhibitor-sparing or -avoidance regimens.
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Introduction
Organ transplantation opened a new era in the treatment of end-stage organ failure. Rejection is still the major obstacle to success because most organ transplantations are carried out between genetically distinct individuals. T cells are the crucial mediators and controllers in graft rejection induced by histoincompatible alloantigens (1) . It is known that full T cell activation requires several collaborative but distinct signals. In addition to the triggered signal generated by the interaction between a TCR and an MHC-bound peptide, costimulatory signals are also essential for T cells to be efficiently activated. In the absence of these signals, T cells will enter a state of proliferative nonresponsiveness and undergo apoptosis (2-4).
Numerous costimulatory molecules have been identified to date. Unlike the targets of conventional immunosuppressants, these molecules are largely limited to T cells and/or antigen-presenting cells (APCs). Targeting costimulatory pathways offers the potential for selective inhibition of alloimmune response. CD28-CD80 (B7-1)/ CD86 (B7-2) is a well-characterized costimulatory receptor/ligand pair. CD28 signals amplify TCR-induced signaling events, promote IL-2 production (5), mediate T cells to enter the cell cycle (6) , increase the generation of cytokines and chemokines (7) , control regulatory T cell (Treg) homeostasis (8) , and reinforce resistance to apoptosis (9) .
Blocking the CD28-CD80/CD86 pathway with cytotoxic T-lymphocyte associated protein 4-immunoglobulin (CTLA4-Ig) has been demonstrated to successfully prevent allograft rejection. Belatacept, a high-affinity variant of CTLA4-Ig, has been approved for clinical use in renal transplantation recipients. Compared with cyclosporinebased regimens, belatacept-based regimens exhibited similar patient and graft survival, superior renal function, and improved metabolic profile (10); however, belatacept was found to be associated with higher rates and grades of acute rejection (AR). In addition, posttransplant lymphoproliferative disorder (PTLD) was observed more frequently in patients treated with belatacept (11, 12) . ASP2409 (Astellas, Tokyo, Japan) is a fusion protein recombining the modified extracellular portion of human CTLA4 (10 amino acid mutations) with the wild-type fragment crystallizable region of human IgG2. This novel CTLA4-Ig variant has binding affinity to human CD80 and CD86 with K D values of 64.2 and 30.0 pM, respectively. That means ASP2409 possesses %14-fold higher CD86 binding affinity compared with belatacept, whereas the CD80 binding affinity of belatacept is 1.8-fold higher than that of ASP2409. Of note, previous CTLA4-Igs including belatacept were all selective for CD80 binding. ASP2409 is a CD86-selective CTLA4-Ig with 2.1-fold higher binding affinity for CD86 than for CD80 (13) .
This study evaluated the effects of ASP2409 on renal allograft survival in nonhuman primates. We found that ASP2409 as monotherapy and in combination with subtherapeutic-dose tacrolimus or mycophenolate mofetil (MMF) significantly prolonged allograft survival. High-dose ASP2409-based regimens showed allograft survival results similar to the belatacept-based regimen and the therapeutic-dose tacrolimus-based regimen and noninferior histopathological results compared with the belatacept-based regimen.
Materials and Methods

Animals
This study used 3.3-to 6.3-kg male cynomolgus monkeys (Macaca fascicularis) that were free of specific pathogens (hepatitis B virus, hepatitis C virus, simian immunodeficiency virus, and herpes B virus) and that were obtained from the Laboratory Animals Center of the Academy of Military Medical Sciences (AMMS) in Beijing, People's Republic of China. All experimental procedures were approved by the Ethical Committee for Animal Experimentation at the Laboratory Animals Center of the AMMS and were performed in accordance with the Guide for the Care and Use of Laboratory Animals. The recipient and donor pairs chosen were ABOantigen compatible with a stimulation index ≥ 2.5 in a one-way mixed lymphocyte reaction, as described previously (14) .
Life-supporting kidney transplantation
Heterotopic renal transplantations were performed, as described previously (15, 16) . Briefly, each animal in this study acted as both donor and recipient. Monkeys were anesthetized by intramuscular injection of ketamine and xylazine, and a midline incision was made to open the abdominal cavity. The left kidney and ureter were removed en bloc and exchanged between paired monkeys. The allograft was implanted 2-4 cm distal to the left native kidney by end-to-side anastomoses of renal artery to aorta and renal vein to vena cava and end-to-end anastomosis of donor and recipient ureters. The right native kidney was removed after the transplanted kidney was reperfused.
Experimental group and treatment
Animals were divided into 12 groups, as follows (Table 1) : no-treatment control, low-dose ASP2409 monotherapy (A0.3), high-dose ASP2409 monotherapy (A1.0), very low-dose tacrolimus monotherapy (T0.5), subtherapeutic-dose tacrolimus monotherapy (T1.0), low-dose ASP2409 combined with subtherapeutic-dose tacrolimus (A0.3T1.0), high-dose ASP2409 combined with very low-dose tacrolimus (A1.0T0.5), high-dose ASP2409 combined with subtherapeutic-dose tacrolimus (A1.0T1.0), lowdose ASP2409 combined with MMF and pridol (methylprednisolone; A0.3MP), high-dose ASP2409 combined with MMF and pridol (A1.0MP), belatacept combined with MMF and pridol (BMP), and therapeutic-dose tacrolimus combined with MMF and pridol (T2.0MP). ASP2409 was provided by Astellas. All procedures for generation and production of ASP2409 were performed under the control of Perseid Therapeutics (Redwood City, CA). ASP2409 was administered subcutaneously at doses of 0.3 or 1 mg/kg (0.2 mL/kg) on posttransplant days (PODs) 0, 4, and 7 and then weekly to day 84. Tacrolimus (Astellas) was administered orally immediately after kidney transplantation and then once daily until day 90. MMF (Hoffmann-La Roche Ltd., Basel, Switzerland) at a dose of 15 mg/kg was given subcutaneously twice daily from PODs 0-14 and then once daily until day 90. Pridol (Alfresa Pharma Corp, Tokyo, Japan) was administered subcutaneously once a day in a tapering manner from POD 0 to 90. Belatacept (Bristol-Myers Squibb, New York, NY) was administered subcutaneously at 5 mg/kg on PODs 0, 4, and 7 and then once weekly to day 84. The study period was 91 days.
Biochemical and hematological determinations
Serum creatinine (sCr) and blood urea nitrogen (BUN) were monitored to determine renal function. Other biochemical parameters including total protein, glucose, amylase, cholesterol, triglyceride, lactate dehydrogenase, albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, total bilirubin and creatine kinase were measured using the autoanalyzer (Beckman Synchron CX5 Pro; Beckman Coulter, Inc., Brea, CA).
Hematological parameters including red blood cell, white blood cell, lymphocyte counts and differential, hemoglobin, hematocrit, and platelet counts were examined in peripheral blood samples using the automated hematology analyzer.
Pharmacokinetics evaluation
Serial serum samples were collected before drug administration on days 0, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84 and on days 16, 30, 58, 86, 91 to measure ASP2409 and belatacept levels. To measure A0.3, low-dose ASP2409 monotherapy; A0.3MP, low-dose ASP2409 combined with mycophenolate mofetil and pridol (methylprednisolone); A0.3T1.0, low-dose ASP2409 combined with subtherapeutic-dose tacrolimus; A1.0, high-dose ASP2409 monotherapy; A1.0MP, high-dose ASP2409 combined with mycophenolate mofetil and pridol; A1.0T0. 
Anti-ASP2409 antibody
Monkey anti-ASP2409 antibodies were detected with electrochemiluminescent immunoassay at Pharmaceutical Product Development (PPD), LLC (Wilmington, NC) under the control of Shin Nippon Biomedical (Kagoshima, Japan). The sampling schedule was the same as that for pharmacokinetic (PK) evaluation for ASP2409.
Pharmacodynamics evaluation
The following mAbs were used in pharmacodynamics evaluation: fluorescein isothiocyanate (FITC) mouse anti-human CD80 clone: L307. For this evaluation, 1 mL heparin-anticoagulated blood was drawn from each monkey using the same sampling schedule as the PK evaluation for ASP2409. CD80 receptor occupancy on MHC-DR-positive (MHC-DR + ) cells and CD86 receptor occupancy on CD14 + cells were evaluated using a binding competition assay with commoditized CD80/CD86 mAbs to detect the mean fluorescence intensity (MFI) of the CD80/86-bound antibody with flow cytometry. The occupancy rate was calculated using the following formula:
Occupancy rate ð%Þ ¼ð½DMFI before treatmentÀ ½DMFI at each time point= ½DMFI before treatmentÞÂ
100; ðDMFI ¼ MFI -MFI controlÞ
Detection of Tregs by immunohistochemical staining assay in paraffin-embedded sections of renal allografts
The infiltration of CD3 + FoxP3 + and CD3 + T cells were examined by immunohistochemistry assay on kidney allograft paraffin sections in monkeys that survived until the end of the study and on normal kidneys that had no therapy or transplantation.
FoxP3 has been reported to be transiently expressed by activated nonregulatory T cells (17) . High infiltration of FoxP3 + cells was observed in samples from kidney allograft with acute cellular rejection (18) . Besides Tregs, these intragraft FoxP3 + cells can also be activated effector T cells.
To minimize the influence of this factor, the staining assay in this study was conducted in renal grafts for which pathological diagnoses were not AR.
Histopathological determinations
All recipient monkeys were subjected to complete gross necropsies. Routine hematoxylin and eosin staining was performed on all paraffinembedded sample sections including kidney graft, liver, pancreas, spleen, heart, lung, stomach, jejunum, thoracic aorta, and mesentery lymph nodes. Kidney graft sections were stained with Masson's Trichrome and Periodic Acid-Schiff. The Banff 97 classification was used for scoring the presence and degree of renal rejection (19) .
Statistical analysis
In this study, all analyses were conducted using SPSS 13 (IBM Corp, Armonk, NY 
Results
Renal allograft survival Renal allograft survival day was recorded according to the following definitions: (i) the final day that the sCr level did not exceed 10 mg/dL; (ii) the day when significant asthenia was observed; (iii) 1 day before the finding of death; (iv) animal survived to the end of study period, described as >91 days. As shown in Table 1 
Renal graft function
Generally, rapid elevation of sCr and BUN levels implied the occurrence of acute graft rejection. The renal function parameters were relatively stable in monkeys that survived long term ( Figures 1A and B) .
Biochemistry
No evidence showed that administration of ASP2409 affected serum liver enzymes, creatinine kinase and other biochemical parameters.
Hematological determinations
Red blood cell counts, hemoglobin and hematocrit decreased shortly after surgery in most groups. These parameters recovered and were stable 2 weeks after surgery.
Body weight and clinical symptoms
Most of the monkey weights remained stable during the study. After recovery from surgery, all monkeys were very active and had good appetites. When AR occurred, however, animals became lethargic, lost appetite and weight, and developed oliguria accompanied by an increase of sCr. A0.3, low-dose ASP2409 monotherapy; A0.3MP, low-dose ASP2409 combined with mycophenolate mofetil and pridol (methylprednisolone); A0.3T1.0, low-dose ASP2409 combined with subtherapeutic-dose tacrolimus; A1.0, high-dose ASP2409 monotherapy; A1.0MP, high-dose ASP2409 combined with mycophenolate mofetil and pridol; A1.0T0.5, high-dose ASP2409 combined with very low-dose tacrolimus; A1.0T1.0, high-dose ASP2409 combined with subtherapeutic-dose tacrolimus; BMP, belatacept combined with mycophenolate mofetil and pridol; BUN, blood urea nitrogen; cum, cumulative; T0.5, very low-dose tacrolimus monotherapy; T1.0, subtherapeutic-dose tacrolimus monotherapy; T2.0MP, therapeutic-dose tacrolimus combined with mycophenolate mofetil and pridol.
PK evaluation Serum ASP2409 concentration: In general, serum concentrations of ASP2409 increased in a dosedependent manner. During the maintenance phase, the mean ASP2409 C trough values in groups treated with lowdose ASP2409 were from below the lower limit of quantification (BLOQ; <0.04 lg/mL) to 0.23 lg/mL, and the mean ASP2409 C 2 days values ranged from BLOQ to 1.10 lg/mL. In contrast, the range of the mean ASP2409 C trough and ASP2409 C 2 days values in groups treated with high-dose ASP2409 were 0.67-4.46 and 3.48-10.80 lg/mL, respectively (Figure 2A ).
Serum belatacept concentration:
The mean belatacept C trough values during maintenance phase ranged from 10.7 to 16.8 lg/mL. The mean belatacept C 2 days values on days 16, 30, 58 and 86 of dosing were 31.7, 29.3, 35.0 and 30.6 lg/mL, respectively ( Figure 2B ).
Blood concentration of tacrolimus:
The profiles of mean concentrations of tacrolimus are illustrated in Figure 2C . The whole-blood tacrolimus concentrations increased in a dose-related manner. The mean tacrolimus C trough values in groups treated with 0. Plasma concentration of MPA: The mean plasma MPA levels are shown in Figure 2D . Generally, the mean MPA C trough and C 1 h values in each group were similar. The mean MPA trough level fluctuated in the range of 0.54-2.60 lg/mL, and the mean MPA C 1 h values ranged from 4.13 to 10.98 lg/mL.
Anti-ASP2409 antibody assay
Monkey anti-ASP2409 antibodies were detected in 17 of 52 ASP2409-treated animals during the maintenance treatment period (Table 1 ). There were four cases in groups treated with high-dose ASP2409 (two of each in groups A1.0T0.5 and A1.0MP). The remaining cases were all found in monkeys treated with low-dose ASP2409. 
Pharmacodynamics evaluation
The CD80 and CD86 receptor occupancy by ASP2409 increased in a dose-dependent manner. The CD86 receptor occupancy rate reached an almost saturated state on POD 7 in all groups treated with high-dose ASP2409 and remained stable in the maintenance phase. The groups treated with low-dose ASP2409 showed slightly lower CD86 receptor occupancy rates on POD 7 than groups treated with high-dose ASP2409, but they dramatically decreased during the maintenance phase. CD80 receptor occupancy by ASP2409 was relatively lower than CD86. The means of CD80 receptor occupancy in groups treated with high-dose ASP2409 were higher than those of groups treated with low-dose ASP2409, especially during the maintenance phase. Compared with ASP2409, belatacept showed higher CD80 receptor occupancy and lower CD86 receptor occupancy ( Figures 3A and B) . As shown in Figure 4 , the percentage of CD3 + FoxP3 + Tregs among total CD3 + T cells was very low in normal monkey kidneys (0.89%). In two combinations of ASP2409 and subtherapeutic-dose tacrolimus, the highdose ASP2409 group exhibited a higher proportion of CD3 + FoxP3 + cells than the low-dose ASP2409 group (4.60% vs. 1.92%, p < 0.05). Substantially higher percentages of CD3 + FoxP3 + cells were seen in renal allografts in groups treated with high-dose ASP2409 combined with MMF (8.51%) and belatacept combined with MMF (7.28%) relative to the combination of therapeutic-dose tacrolimus and MMF (2.41%).
Histopathology
The details of histological features of transplanted kidneys are summarized in Table 1 . All renal allografts in the no-treatment control and low-dose ASP2409 monotherapy groups exhibited AR. AR was also found in most transplanted kidneys in groups treated with very low-dose tacrolimus monotherapy (7 of 8) and with lowdose ASP2409 combined with MMF and pridol (7 of 8). The incidence of AR was significantly decreased in groups treated with subtherapeutic-dose tacrolimus monotherapy (3 of 8), high-dose ASP2409 monotherapy (2 of 7), high-dose ASP2409 combined with MMF and pridol (1 of 8), and belatacept combined with MMF and pridol (1 of 7). No AR was discovered in groups treated with high-dose ASP2409 combined with very low-dose tacrolimus, low-dose ASP2409 combined with subtherapeutic-dose tacrolimus, high-dose ASP2409 combined with subtherapeutic-dose tacrolimus, and therapeutic dose tacrolimus combined with MMF and pridol. Varying degrees of chronic allograft nephropathy were the common pathological changes observed in animals that survived long term. Some animals in various cohorts displayed no rejection.
Discussion
Calcineurin inhibitors (CNIs) are still the cornerstone for maintenance therapy in organ transplantation; however, the extensive adverse effects of CNIs may cause graft dysfunction, loss and/or patient death and affect the longterm outcomes of organ transplants. Several therapeutic regimens such as CNI reduction, avoidance and early withdrawal have been tested to minimize the consequences associated with CNI exposure (20, 21) . The reported results of these immunosuppressive regimens have shown mixed results. Some regimens increased the risk of acute and chronic rejection (22, 23) . The belatacept-based regimens shed light on CNI avoidance protocols. Through a series of renal transplantation clinical trials, belatacept-based regimens were demonstrated to confer patient and graft survival rates similar to cyclosporine-based regimens as well as superior renal function and an improved metabolic profile (10-12,24). Unfortunately, higher incidence of AR and PTLD is the potential "Achilles' heel" of belatacept, slowing the progress of this novel agent for other organ transplant clinical applications (11, 25) .
CD28 signaling plays a pivotal role in T cell activation, especially in the early posttransplant stage. Of the two natural ligands for CD28, CD86 exhibits higher affinity than CD80. In contrast, CD80 has higher binding affinity for CTLA4 (26, 27) . For the purpose of durably suppressing allograft rejection, complete and equal blockade of the costimulatory pathway is required (28) . To develop new CTLA4-Ig proteins, which possess more potent immunosuppressive properties than current CTLA4-Igs, it is reasonable to engineer a molecule with higher binding affinity for the B7 ligands, especially CD86. ASP2409 is designed to reach this goal. In vitro pharmacology studies indicated that, compared with abatacept and belatacept, human CD86 binding affinity was increased by 220-fold and 14-fold, respectively, with this new-generation CTLA4-Ig (13) . The in vivo tests in cynomolgus monkeys showed that ASP2409 dose-dependently inhibited antitetanus toxoid antibody production and delayed-type hypersensitivity reactions. When the dosage reached 1 mg/kg, ASP2409 showed an almost completely inhibitory effect on both tetanus toxoid antibody production and delayed-type hypersensitivity reactions, whereas belatacept at 10 mg/kg showed just partial suppression (Oshima S, Karrer EE, Kawato Y, et al. The Effect of ASP2409, A Novel CD86-Selective Variant of CTLA4-Ig, on Renal Allograft Rejection in Nonhuman Primates. Transplantation. In press.).
ASP2409 monotherapy dose-dependently prolonged the MST of allografts. Low-dose (0.3 mg/kg) ASP2409 monotherapy showed significantly longer MST compared with no-treatment control; however, ARs were only delayed, not eliminated, in this group. This implies that ASP2409 0.3 mg/kg is not a therapeutic dose for allograft rejection. Interestingly, when this dosage of ASP2409 was combined with subtherapeutic-dose tacrolimus (29) , the MST dramatically increased and AR was totally abolished. When the dosage of ASP2409 was increased to 1 mg/kg, more than half of the animals in this monotherapy group survived to the end of the study, and the incidence of AR was significantly reduced. This dosage of ASP2409 in combination with either subtherapeutic-dose tacrolimus or MMF plus pridol revealed MSTs comparable to belatacept-based and therapeutic-dose tacrolimusbased regimens. Histopathological findings from kidney grafts in the group treated with high-dose ASP2409 combined with subtherapeutic-dose tacrolimus were similar to those treated with therapeutic-dose tacrolimus and MMF plus pridol. These data collectively imply that ASP2409 may work for both CNI-sparing and -avoidance regimens.
Serum concentrations of ASP2409 increase in a doserelated manner. Compared with low-dose groups, ASP2409 C trough and C 2 days values in high-dose groups showed relatively low variability. It is known that CD86 receptor saturation correlates with inhibition of T cell alloresponses (30) . In the induction phase, at either high or low dose, ASP2409 exhibited higher CD86 receptor occupancy than belatacept. The high level of CD86 receptor occupancy remained in ASP2409 high-dose groups in the The mean level of CD86 receptor occupancy in each group. The rate of CD86 receptor occupancy by ASP2409 increased dose dependently. In the maintenance phase, groups treated with high-dose ASP2409 exhibited high levels of CD86 receptor occupancy, whereas CD86 receptor occupancy in groups treated with lowdose ASP2409 decreased dramatically. ASP2409 showed a higher percentage of CD86 receptor occupancy than belatacept. It is consistent with the design of ASP2409 to possess higher CD86 binding affinity than belatacept. A0.3, low-dose ASP2409 monotherapy; A0.3MP, low-dose ASP2409 combined with mycophenolate mofetil and pridol (methylprednisolone); A0.3T1.0, low-dose ASP2409 combined with subtherapeutic-dose tacrolimus; A1.0, high-dose ASP2409 monotherapy; A1.0MP, high-dose ASP2409 combined with mycophenolate mofetil and pridol; A1.0T0.5, high-dose ASP2409 combined with very low-dose tacrolimus; A1.0T1.0, high-dose ASP2409 combined with subtherapeutic-dose tacrolimus; BMP, belatacept combined with mycophenolate mofetil and pridol. maintenance phase. It is consistent with the design of ASP2409 to possess higher CD86 binding affinity; however, with the low ASP2409 C trough during the maintenance phase, the levels of CD86 receptor occupancy in ASP2409 low-dose groups dramatically decreased. The development of anti-ASP2409 antibodies was confirmed in 17 of 52 animals (%33%) following administration of ASP2409 during the maintenance period. A partial reason for the high incidence of anti-ASP2409 antibodies in this study could be attributed to ASP2409, which, as a human protein, is a foreign antigen for monkeys. In contrast, the incidence of anti-ASP2409 antibodies in animals treated with high-dose ASP2409 (%14%) was much lower than that in animals treated with low-dose ASP2409 (%57%). This result implies that higher doses of ASP2409 may inhibit the production of anti-ASP2409 antibodies. High incidence of anti-ASP2409 antibodies in animals treated with low-dose ASP2409 corresponds to low ASP2409 C trough values and decreased CD80 and CD86 receptor occupancies. A possible explanation for this phenomenon is that anti-ASP2409 antibodies neutralize the biological activity of ASP2409 and/or lower its half life in the circulatory system (31, 32) .
Tregs are important regulators of immune tolerance. CD28 signals play a key role in the development of Tregs in the thymus. CD28 costimulation is also critical for the survival of peripheral Tregs (33, 34) . This raises a concern that targeting the CD28-CD80/CD86 pathway may interfere with Treg development and peripheral expansion. CTLA4-Ig has been reported to have a deleterious effect on Treg development and function in animal models (35) and inhibits in vitro human Treg generation (36) . This agent is also found to restore skin allograft rejection in a Treg-mediated tolerance model by disabling IL-2-expanded Tregs (37) . In contrast, a report indicated that CTLA4-Ig induced in vitro swine Treg generation via an IL-10-dependent mechanism (38) . In renal transplant patients who received belatacept-based regimens, belatacept administration did not affect the number or function of circulating Tregs (39) . The effects of CTLA4-Ig on Treg generation and function may be complicated.
It has been reported that CD28 costimulation is unnecessary for the generation or function of induced Tregs, whereas the development and maintenance of natural Tregs are strongly dependent on CD28-CD80/CD86 signals (40) . In addition, the effects of CTLA4-Ig on the CTLA4 signaling pathway are still unclear. Further investigation is helpful to explore the overall profile of the effects of CTLA4-Ig on Tregs. In this study, we did not measure the number of circulating Tregs. Interestingly, we found that renal allografts treated with ASP2409-or belatacept-based regimens exhibited significantly higher proportions of FoxP3 + /CD3 + T cells than normal kidney and renal allografts treated with CNI-based regimens. The situation is similar to what is found in graft biopsies of patients who are treated with belatacept-based regimens (39) . These findings suggest that both ASP2409 and belatacept may have no significant deleterious effect on the frequency of Tregs in renal allografts.
In this study, ASP2409 was administered to cynomolgus monkey kidney transplant recipients as an immunosuppressive agent for up to 90 days. Treatment with ASP2409 did not cause deterioration in the general clinical observational signs including daily activity and appetite. In addition, no weight loss or other side effects were associated with ASP2409 administration during the study period. ASP2409 was demonstrated to be safe and well tolerated by the monkeys at the doses tested.
We conclude that ASP2409 exhibits potent immunosuppressive effects on the monkey renal transplantation model without causing serious side effects. When administered alone, this agent dose-dependently prolongs renal allograft survival. ASP2409 in combination with subtherapeutic-dose tacrolimus or MMF plus pridol shows MSTs similar to the belatacept-and tacrolimusbased regimens for the 91-day observation period. Histopathological findings from kidney grafts using the ASP2409-based regimen are noninferior to the belatacept-based regimen. Chronic administration of ASP2409 does not negatively affect Treg frequency in renal allografts. These results suggest that ASP2409 is a promising candidate for CNI-sparing or -avoidance regimens.
